Prognostic biomarkers in diffuse large B-cell lymphoma.

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma. Although it represents a curable disease, less than half of the patients are cured with conventional chemotherapy. The highly variable outcome reflects a heterogeneous group of tumors, with different genetic abnormalities and response to therapy. The International Prognostic Index (IPI) is useful in predicting the outcome of DLBCL patients. However, patients with identical IPI still exhibit marked variability in survival, suggesting the presence of significant residual heterogeneity within each IPI category. The discovery of specific genetic alterations and the assessment of protein expression led to the identification of multiple novel single molecular markers capable of predicting the outcome of DLBCL patients independently of clinical variables. The recent application of DNA microarrays and tissue array technologies allowed a better understanding of the biology of lymphoma and the development of novel diagnostic tools capable of improving the current models for outcome prediction. However, much confusion exists in the literature regarding the importance of different prognostic biomarkers and their applicability in routine practice. This review summarizes the recent advances in our understanding of prognostic biomarkers in DLBCL and discusses whether this is the right time for biomarkers-guided risk-adjusted therapy.

[1]  G Flandrin,et al.  World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  H. Koga,et al.  Prognostic significance of the F‐box protein Skp2 expression in diffuse large B‐cell lymphoma , 2003, American journal of hematology.

[3]  A. Gearing,et al.  Design and therapeutic application of matrix metalloproteinase inhibitors. , 1999, Chemical reviews.

[4]  M Tubiana,et al.  Report of the Committee on Hodgkin's Disease Staging Classification. , 1971, Cancer research.

[5]  G Flandrin,et al.  The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  William Arbuthnot Sir Lane,et al.  Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.

[7]  P. Marynen,et al.  FOXP1, a gene highly expressed in a subset of diffuse large B-cell lymphoma, is recurrently targeted by genomic aberrations , 2005, Leukemia.

[8]  S. Fox,et al.  Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms. , 1994, Cancer research.

[9]  K. Offit,et al.  BCL-6 protein is expressed in germinal-center B cells. , 1995, Blood.

[10]  Tetsuo Himi,et al.  Expression of matrix metalloproteinase 9 is a prognostic factor in patients with non‐Hodgkin lymphoma , 2004, Cancer.

[11]  H. Joensuu,et al.  Elevated serum endostatin is associated with poor outcome in patients with non‐Hodgkin lymphoma , 2003, Cancer.

[12]  R. Friesel,et al.  Molecular mechanisms of angiogenesis: fibroblast growth factor signal transduction , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[13]  Katia Basso,et al.  Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma. , 2003, Blood.

[14]  T M Grogan,et al.  Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[15]  L. Staudt,et al.  Transcriptional repression by the proto-oncogene BCL-6. , 1996, Oncogene.

[16]  Emili Montserrat,et al.  Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. , 2003, Blood.

[17]  C. Mackay,et al.  Expression and modulation of CD44 variant isoforms in humans , 1994, The Journal of cell biology.

[18]  G. Pinkus,et al.  Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD. , 1986, Annals of internal medicine.

[19]  H. Dvorak,et al.  Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. , 1999, Current topics in microbiology and immunology.

[20]  A. Levine p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[21]  J. Blay,et al.  Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor. , 1993, Blood.

[22]  Harold E. Dvorak,et al.  Angiogenesis: a Dynamic Balance of Stimulators and Inhibitors , 1997, Thrombosis and Haemostasis.

[23]  D. Rifkin,et al.  Biological roles of fibroblast growth factor-2. , 1997, Endocrine reviews.

[24]  F. Mitelman,et al.  Prognostic implications of BCL6 rearrangement in uniformly treated patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study. , 2002, International journal of oncology.

[25]  C. Meijer,et al.  Prognostic significance of activated cytotoxic T-lymphocytes in primary nodal diffuse large B-cell lymphomas , 2004, Leukemia.

[26]  B. Nathwani,et al.  A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma: a report of the Non-Hodgkin's Lymphoma Classification Project , 1997 .

[27]  S. Jagannath,et al.  Risk classification as the basis for clinical staging of diffuse large-cell lymphoma derived from 10-year survival data. , 1989, Blood.

[28]  H. Joensuu,et al.  A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. , 1997, Blood.

[29]  T. Molina,et al.  CD10 expression in diffuse large B-cell lymphomas does not influence survival , 2004, Virchows Archiv.

[30]  S. Barrans,et al.  Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome. , 2004, Blood.

[31]  S. Jalkanen,et al.  Serum CD44 in malignant lymphoma: an association with treatment response. , 1994, Blood.

[32]  T. Grogan,et al.  Tumor-infiltrating T-lymphocytes in B-cell diffuse large cell lymphoma related to disease course. , 1990, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[33]  J Diebold,et al.  Prognostic significance of survivin expression in diffuse large B-cell lymphomas. , 2000, Blood.

[34]  R. Tibshirani,et al.  Molecular analysis of immunoglobulin genes in diffuse large B-cell lymphomas. , 2000, Blood.

[35]  M. Radmacher,et al.  Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. , 2003, Journal of the National Cancer Institute.

[36]  Ash A. Alizadeh,et al.  Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. , 2004, The New England journal of medicine.

[37]  H. Müller-Hermelink,et al.  Genetic analysis of de novo CD5+ diffuse large B-cell lymphomas suggests an origin from a somatically mutated CD5+ progenitor B cell. , 2003, Blood.

[38]  M. Piris,et al.  © 1999 Cancer Research Campaign Article no. bjoc.1999.0539 p27 KIP1 is abnormally expressed in Diffuse Large B-Cell , 2022 .

[39]  G. Salles,et al.  Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. , 2004, Blood.

[40]  J. Bell,et al.  Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[41]  R. Gascoyne,et al.  Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[42]  Robert Tibshirani,et al.  HGAL is a novel interleukin-4-inducible gene that strongly predicts survival in diffuse large B-cell lymphoma. , 2003, Blood.

[43]  S. Korsmeyer,et al.  Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around Jh on chromosome 14 and near a transcriptional unit on 18 , 1985, Cell.

[44]  H. Dvorak,et al.  Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. , 1995, The American journal of pathology.

[45]  K. Karube,et al.  Prognostic significance of hepatocyte growth factor and c‐MET expression in patients with diffuse large B‐cell lymphoma , 2004, British journal of haematology.

[46]  S. Tucker,et al.  International prognostic index‐based outcomes for diffuse large B‐cell lymphomas , 2002, Cancer.

[47]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[48]  Geoffrey J McLachlan,et al.  Selection bias in gene extraction on the basis of microarray gene-expression data , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[49]  S. Barrans,et al.  Rearrangement of the BCL6 locus at 3q27 is an independent poor prognostic factor in nodal diffuse large B‐cell lymphoma , 2002, British journal of haematology.

[50]  P. Pandolfi,et al.  The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation , 1997, Nature Genetics.

[51]  L. Staudt,et al.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.

[52]  Ash A. Alizadeh,et al.  The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. , 2002, Blood.

[53]  D. Fearon,et al.  Regulation of B lymphocyte responses to foreign and self-antigens by the CD19/CD21 complex. , 2000, Annual review of immunology.

[54]  S. Jalkanen,et al.  Elevated serum CD44 level is associated with unfavorable outcome in non-Hodgkin's lymphoma. , 1997, Blood.

[55]  T. Grogan,et al.  Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki-67. , 1988, Blood.

[56]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[57]  D. Altieri,et al.  A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma , 1997, Nature Medicine.

[58]  J Hermans,et al.  Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. , 1998, Blood.

[59]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[60]  Y. Honma,et al.  Serum nm23-H1 protein as a prognostic factor in aggressive non-Hodgkin lymphoma. , 2001, Blood.

[61]  R. Schreiber,et al.  Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death , 1990, Nature.

[62]  K. Franssila,et al.  BCL2 overexpression associated with chromosomal amplification in diffuse large B-cell lymphoma. , 1997, Blood.

[63]  T. Golub,et al.  The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. , 2003, Blood.

[64]  L. Pasqualucci,et al.  Distribution and pattern of BCL-6 mutations throughout the spectrum of B-cell neoplasia. , 2000, Blood.

[65]  R Tibshirani,et al.  Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. , 2001, Blood.

[66]  Prognostic models for diffuse large b‐cell lymphoma , 2000, Hematological oncology.

[67]  J Hermans,et al.  Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  C. Sherr Cancer Cell Cycles , 1996, Science.

[69]  Yasodha Natkunam,et al.  Expression of the human germinal center-associated lymphoma (HGAL) protein, a new marker of germinal center B-cell derivation. , 2004, Blood.

[70]  K. Ohshima,et al.  Prognostic clinicopathologic factors, including immunologic expression in diffuse large B‐cell lymphomas , 1999, Pathology international.

[71]  I. Marugán,et al.  Soluble intercellular adhesion molecule-1 (s-ICAM-1/s-CD54) in diffuse large B-cell lymphoma: association with clinical characteristics and outcome. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[72]  P. Herrlich,et al.  Activated human lymphocytes and aggressive non-Hodgkin's lymphomas express a homologue of the rat metastasis-associated variant of CD44 , 1993, The Journal of experimental medicine.

[73]  A. López-Guillermo,et al.  Expression of the adhesion molecule ICAM-1 in non-Hodgkin's lymphoma: relationship with tumor dissemination and prognostic importance. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  P. Mclaughlin,et al.  A proposal for a simple staging system for intermediate grade lymphoma and immunoblastic lymphoma based on the 'tumor score'. , 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

[75]  Z. Werb,et al.  How matrix metalloproteinases regulate cell behavior. , 2001, Annual review of cell and developmental biology.

[76]  C. Gundy,et al.  Immunohistochemical profiling of caspase signaling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas. , 2005, Blood.

[77]  S. Kvaløy,et al.  Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma—a Nordic Lymphoma Group study , 2004, Annals of Hematology.

[78]  Ash A. Alizadeh,et al.  The lymphochip: a specialized cDNA microarray for the genomic-scale analysis of gene expression in normal and malignant lymphocytes. , 1999, Cold Spring Harbor symposia on quantitative biology.

[79]  P. Gaulard,et al.  p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[80]  L. Staudt,et al.  Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. , 2004, Blood.

[81]  W. Chan,et al.  Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma , 2005, Modern Pathology.

[82]  Rosenberg Sa Validity of the Ann Arbor staging classification for the non-Hodgkin's lymphomas. , 1977 .

[83]  R S Chaganti,et al.  BCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[84]  K. Ohshima,et al.  CD10 and Bcl10 expression in diffuse large B‐cell lymphoma: CD10 is a marker of improved prognosis , 2001, Histopathology.

[85]  H. Nakamine,et al.  Clinical Significance of Intracytoplasmic nm23-H1 Expression in Diffuse Large B-Cell Lymphoma , 2004, Clinical Cancer Research.

[86]  T. Lebien,et al.  The common acute lymphoblastic leukemia antigen (CD10)--emancipation from a functional enigma. , 1989, Blood.

[87]  J Diebold,et al.  Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). , 1996, Blood.

[88]  H. Shiku,et al.  De novo CD5+ diffuse large B-cell lymphomas express VH genes with somatic mutation. , 1998, Blood.

[89]  M. Teitell,et al.  PKC-β controls IκB kinase lipid raft recruitment and activation in response to BCR signaling , 2002, Nature Immunology.

[90]  Ellen,et al.  Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial. , 1994, Blood.

[91]  N. Ferrara,et al.  The biology of vascular endothelial growth factor. , 1997, Endocrine reviews.

[92]  H Stein,et al.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.

[93]  J. Cheville,et al.  p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. , 1999, The American journal of pathology.

[94]  S. Tucker,et al.  A new serologic staging system for large-cell lymphomas based on initial beta 2-microglobulin and lactate dehydrogenase levels. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[95]  S. Rosenberg Validity of the Ann Arbor staging classification for the non-Hodgkin's lymphomas. , 1977, Cancer treatment reports.

[96]  J C Reed,et al.  Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. , 1997, Blood.

[97]  Takashi Akasaka,et al.  De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. , 2002, Blood.

[98]  S. le Cessie,et al.  Lack of Prognostic Significance of BCL2 and p53 Protein Overexpression in Elderly Patients with Diffuse Large B-cell Non-Hodgkin's Lymphoma: Results from a Population-based Non-Hodgkin's Lymphoma Registry , 2004, Leukemia & lymphoma.

[99]  H. Joensuu,et al.  Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients. , 2000, Blood.

[100]  G. Fountzilas,et al.  Diffuse Large Cell Lymphomas: Identification of Prognostic Factors and Validation of the International Non-Hodgkin’s Lymphoma Prognostic Index , 1998, Oncology.

[101]  U. Jaeger,et al.  Cyclin D3 is a predictive and prognostic factor in diffuse large B-cell lymphoma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[102]  S. Sohn,et al.  Prognostic significance of bcl‐2, bax, and p53 expression in diffuse large B‐cell lymphoma , 2003, American journal of hematology.

[103]  J. Cigudosa,et al.  Chromosomal and gene amplification in diffuse large B-cell lymphoma. , 1998, Blood.

[104]  P. Johnson,et al.  The prognostic significance of serum levels of soluble intercellular adhesion molecules‐1 in patients with primary extranodal non‐Hodgkin lymphomas , 2000, Cancer.

[105]  S. Jagannath,et al.  Tumor burden assessment and its implication for a prognostic model in advanced diffuse large-cell lymphoma. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[106]  T. Grogan,et al.  HLA-DR (Ia) immune phenotype predicts outcome for patients with diffuse large cell lymphoma. , 1988, The Journal of clinical investigation.

[107]  R. Coffman,et al.  Interleukin-10 and the interleukin-10 receptor. , 2001, Annual review of immunology.

[108]  F. Mandelli,et al.  Pathogenetic and clinical implications of Bcl‐6 and Bcl‐2 gene configuration in nodal diffuse large B‐cell lymphomas , 1997, The Journal of pathology.

[109]  S. Poppema,et al.  Human marginal zone b cells are not an activated b cell subset: strong expression of cd21 as a putative mediator for rapid b cell activation , 1989, European journal of immunology.

[110]  M. Teitell,et al.  PKC-beta controls I kappa B kinase lipid raft recruitment and activation in response to BCR signaling. , 2002, Nature immunology.

[111]  Motohiro Ito,et al.  CD21S antigen expression in tumour cells of diffuse large B‐cell lymphomas is an independent prognostic factor indicating better overall survival , 2004, British journal of haematology.

[112]  A. Naganuma,et al.  Negative autoregulation of BCL-6 is bypassed by genetic alterations in diffuse large B cell lymphomas , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[113]  Adrian Wiestner,et al.  A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[114]  Ramón Bosch,et al.  Building an outcome predictor model for diffuse large B-cell lymphoma. , 2004, The American journal of pathology.

[115]  G. Pinkus,et al.  The m-BACOD combination chemotherapy regimen in large-cell lymphoma: analysis of the completed trial and comparison with the M-BACOD regimen. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[116]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[117]  D C Linch,et al.  Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation Study. , 1996, Blood.

[118]  T. Grogan,et al.  Loss of B7.2 (CD86) and intracellular adhesion molecule 1 (CD54) expression is associated with decreased tumor-infiltrating T lymphocytes in diffuse B-cell large-cell lymphoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[119]  M. Hollstein,et al.  p53 and human cancer: the first ten thousand mutations. , 2000, Advances in cancer research.

[120]  Atul Butte,et al.  The use and analysis of microarray data , 2002, Nature Reviews Drug Discovery.

[121]  Meland,et al.  The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[122]  H. Tilly,et al.  LAZ3, a novel zinc–finger encoding gene, is disrupted by recurring chromosome 3q27 translocations in human lymphomas , 1993, Nature Genetics.

[123]  H. Saito,et al.  Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. , 1997, The New England journal of medicine.

[124]  S. Pals,et al.  Cell adhesion receptors in lymphoma dissemination. , 2000, Blood.

[125]  LAZ3 rearrangements in non-Hodgkin's lymphoma: correlation with histology, immunophenotype, karyotype, and clinical outcome in 217 patients , 1994 .

[126]  P. Gaulard,et al.  Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). , 2003, Blood.

[127]  M. Ladanyi,et al.  Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma. , 1994, The New England journal of medicine.

[128]  M. Piccinni,et al.  T lymphocytes from invaded lymph nodes in patients with B-cell-derived non-Hodgkin's lymphoma: reactivity toward the malignant clone. , 1990, Blood.

[129]  J. Banchereau,et al.  Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[130]  J. Sklar,et al.  Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[131]  J. Armitage,et al.  Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[132]  Todd,et al.  Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning , 2002, Nature Medicine.